Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Congenital Hyperinsulinism Treatment Market Snapshot (2023 to 2033)

The global congenital hyperinsulinism treatment market is expected to garner a market value of US$ 100 Million in 2023 and is expected to accumulate a market value of US$ 179.08 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Congenital Hyperinsulinism registered a CAGR of 4% in the historical period 2017 to 2022.

Diabetes is a most common health problem causing high blood sugar levels resulting in excessive thirst and large amounts of urine production. It causes secondary health-associated problems such as diabetic ketoacidosis, hyperosmolar hyperglycemic states, and other serious complications (heart attack, stroke, kidney failure, leg amputation) leading to premature death.

The growing number of patients suffering from diabetes will accelerate the market growth rate. Moreover, increasing awareness among physicians and patients about the benefits of Congenital Hyperinsulinism will provide beneficial opportunities for the growth of the Congenital Hyperinsulinism Treatment market.

Report Attribute Details
Expected Market Value (2023) US$ 100 Million
Anticipated Forecast Value (2033) US$ 179.08 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Congenital Hyperinsulinism Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Congenital Hyperinsulinism reflected a value of 4% during the historical period, 2017 to 2022. Various factors such as awareness of wellness and health and the rising geriatric population suffering from diabetes are projected to drive the market growth.

In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Congenital Hyperinsulinism treatment is fuelling the market growth. Thus, the market for Congenital Hyperinsulinism is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Congenital Hyperinsulinism Treatment Market?

Strong Relation Between Diabetes & Congenital Hyperinsulinism to push the market growth

The increasing prevalence of Congenital Hyperinsulinism disease is one of the biggest drivers of the market. As per studies, Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Furthermore, studies suggest that about 60% of babies with HI are diagnosed during the first month of life. An additional 30% will be diagnosed later in the first year and the remainder after that. With early treatment and aggressive prevention of hypoglycemia, brain damage can be prevented. However, brain damage can occur in children with HI if the condition is not recognized or if treatment is ineffective in the prevention of hypoglycemia.

The massive growth in the diabetic population is primarily attributable to rising Congenital Hyperinsulinism rates around the world, as well as sedentary lifestyles defined by poor diets and decreased physical exercise.

Furthermore, a strong relationship between diabetes and Congenital Hyperinsulinism has been proven by certain studies. For instance, NCBI states that β cell failure in type 2 diabetes (T2D) is associated with hyperglycemia, but the mechanisms are not fully understood. Congenital hyperinsulinism caused by glucokinase mutations (GCK-CHI) is associated with β cell replication and apoptosis. Here, we show that genetic activation of β cell glucokinase, initially triggering replication, causes apoptosis associated with DNA double-strand breaks and activation of the tumor suppressor p53.

Considering these in-depth studies, the market is projected to show considerable growth through 2033.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Congenital Hyperinsulinism Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Congenital Hyperinsulinism, less awareness of Congenital Hyperinsulinism disease, and insubstantial treatment options are hampering the market growth.

Region-Wise Insights

How is the Market for Congenital Hyperinsulinism Treatment Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling growth of Congenital Hyperinsulinism in Asia Pacific

The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of Congenital Hyperinsulinism treatment in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.

What are the Factors Boosting the Market for Congenital Hyperinsulinism in North America?

Technological Advancements Shaping Landscape for Congenital Hyperinsulinism in North America

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Application, Which End-User is Likely to Account for the Highest Share?

Hospitals to take the lead and drive market growth

The application segment has been divided into hospitals, retail pharmacies, and Ambulatory Surgical Centres. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during Congenital Hyperinsulinism treatment facilitates the growth of this segment.

Start-ups in the Congenital Hyperinsulinism Treatment Market

Key start-up players in the Congenital Hyperinsulinism Treatment Market are-

  • Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announced the completion of a seed funding round. Xinvento was founded in 2021 by CEO Claudine van der Sande, the driving force behind the company, who has a son diagnosed with Congenital Hyperinsulinism (CHI). This seed funding will enable Xinvento to design and test its proprietary molecules in the relevant pre-clinical models to identify potential drug candidates.
  • Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI) and has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) & hereditary angioedema (HAE). In Dec 2017, the company entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.

Market Competition

Key players in the Congenital Hyperinsulinism Treatment Market are Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, and Xeris Pharmaceuticals, Inc.

  • In September 2022, Novo Nordisk and Microsoft entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities. Through the partnership, Microsoft is providing AI technology, foundational science models, and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s Research and Development.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 100 Million
Market Value in 2033 US$ 179.08 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Procedure
  • Application
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa(MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC Countries
  • South Africa
Key Companies Profiled Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, Xeris Pharmaceuticals, Inc
Customization Available Upon Request

Key Segments Profiled in the Congenital Hyperinsulinism Industry Survey

Treatment Method:

  • Drug Therapy
    • Diazoxide
    • Octreotide
    • Glucagon
    • Others
  • Surgery

Application:

  • Hospitals
  • Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa(MEA)

Frequently Asked Questions

What is the Congenital Hyperinsulinism Treatment Market CAGR for 2033?

The congenital hyperinsulinism treatment market CAGR for 2033 is 6%.

How Big Will the Congenital Hyperinsulinism Treatment Market by 2033?

The market is estimated to reach US$ 179.08 million by 2033.

How Key Players are Developing the Congenital Hyperinsulinism Treatment Market?

Key congenital hyperinsulinism treatment market players are introducing new and innovative therapies.

What is the Current Congenital Hyperinsulinism Treatment Market Valuation?

The market is estimated to secure a valuation of US$ 100 million in 2023.

Who are the Three Key Players in the Congenital Hyperinsulinism Treatment Market?

Zealand, Rezolute, and Xeris are the three key congenital hyperinsulinism treatment market players.

Table of Content

1. Executive Summary | Congenital Hyperinsulinism Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Methods

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Methods, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Methods, 2023 to 2033

        5.3.1. Drug Therapy

            5.3.1.1. Diazoxide

            5.3.1.2. Octreotide

            5.3.1.3. Glucagon

            5.3.1.4. Others

        5.3.2. Surgery

    5.4. Y-o-Y Growth Trend Analysis By Treatment Methods, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Methods, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa(MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Treatment Methods

        8.2.3. By Application

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment Methods

        8.3.3. By Application

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment Methods

        9.2.3. By Application

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Methods

        9.3.3. By Application

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment Methods

        10.2.3. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Methods

        10.3.3. By Application

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Treatment Methods

        11.2.3. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Methods

        11.3.3. By Application

    11.4. Key Takeaways

12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of Middle East and Africa(MEA)

        12.2.2. By Treatment Methods

        12.2.3. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Methods

        12.3.3. By Application

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Treatment Methods

            13.1.2.2. By Application

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Treatment Methods

            13.2.2.2. By Application

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Treatment Methods

            13.3.2.2. By Application

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Treatment Methods

            13.4.2.2. By Application

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Treatment Methods

            13.5.2.2. By Application

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Treatment Methods

            13.6.2.2. By Application

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Treatment Methods

            13.7.2.2. By Application

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Treatment Methods

            13.8.2.2. By Application

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Treatment Methods

            13.9.2.2. By Application

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Treatment Methods

            13.10.2.2. By Application

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Treatment Methods

            13.11.2.2. By Application

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Treatment Methods

            13.12.2.2. By Application

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Treatment Methods

            13.13.2.2. By Application

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Treatment Methods

            13.14.2.2. By Application

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Treatment Methods

            13.15.2.2. By Application

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Treatment Methods

            13.16.2.2. By Application

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Treatment Methods

            13.17.2.2. By Application

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Treatment Methods

            13.18.2.2. By Application

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Treatment Methods

            13.19.2.2. By Application

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Treatment Methods

            13.20.2.2. By Application

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Treatment Methods

        14.3.3. By Application

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Eli Lilly

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Novo Nordisk

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Novartis AG

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Rezolute, Inc.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Eiger BioPharmaceuticals.

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Zealand Pharma A/S

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Hanmi Pharmaceutical Co., Ltd.

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Crinetics Pharmaceuticals, Inc.

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. AmideBio LLC

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Xeris Pharmaceuticals, Inc

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 14: Global Market Attractiveness by Application, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 29: North America Market Attractiveness by Application, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 59: Europe Market Attractiveness by Application, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Treatment Methods, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 88: MEA Market Attractiveness by Treatment Methods, 2023 to 2033

Figure 89: MEA Market Attractiveness by Application, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Leukemia Therapeutics Treatment Market

Published : October 2023

Healthcare

Treatment-Resistant Depression Treatment Market

Published : December 2022

Healthcare

Diabetes Care Devices Market

Published : July 2022

Explore Healthcare Insights

View Reports

Congenital Hyperinsulinism Treatment Market